{"id":"NCT00654498","sponsor":"Boehringer Ingelheim","briefTitle":"Pramipexole in Out-patients With Idiopathic Restless Legs Syndrome (IRLS)","officialTitle":"A Randomized, Double-blind, Placebo Controlled Dose Titration Trial With 0.125-0.75 mg Pramipexole (SifrolÂ®) Orally q.n. to Investigate the Safety and Efficacy in Out-patients With Idiopathic Restless Legs Syndrome for 6 Weeks","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-04","primaryCompletion":"2009-06","completion":"2009-06","firstPosted":"2008-04-08","resultsPosted":"2010-03-03","lastUpdate":"2014-06-09"},"enrollment":306,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Restless Legs Syndrome"],"interventions":[{"type":"DRUG","name":"Pramipexole","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Pramipexole","type":"OTHER"},{"label":"Placebo","type":"OTHER"}],"summary":"To determine efficacy and safety of Pramipexole 0.125mg to 0.75mg daily for 6 weeks compared to placebo in the treatment of idiopathic Restless Legs Syndrome (RLS)","primaryOutcome":{"measure":"The Change From Baseline to Week 6 in the Total Score of Restless Legs Syndrome Rating Scale for Severity of the International Restless Legs Syndrome Study Group (IRLS).","timeFrame":"Baseline and 6 weeks of treatment","effectByArm":[{"arm":"Pramipexole","deltaMin":-15.87,"sd":0.66},{"arm":"Placebo","deltaMin":-11.35,"sd":0.92}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":16,"countries":["China"]},"refs":{"pmids":[],"seeAlso":["http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/248/248.630_Literature.pdf"]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":202},"commonTop":["Dizziness","Somnolence","Nausea","Headache","Insomnia"]}}